Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans

MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment

GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNANegative Net Change

Sundeep Ganoria

Should You Buy Moderna Stock Ahead of Q3 Earnings Report?

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNANegative Net Change